Novo Holdings completes acquisition of Catalent (CTLT) following approval by EU Regulators, fulfilling all regulatory closing conditions. Since the last earnings report, the price of Catalent (CTLT) has risen by 3.2%. Notably, Oddo BHF Asset Management Sas has purchased 140,000 shares in Catalent. The company has also seen an increase in investment with other firms such as Fmr LLC, National Bank of Canada FI, UBS ASSET MANAGEMENT AMERICAS LLC, and Readystate Asset Management LP increasing their stakes significant stakes in the company. However, Barclay's, Janus Henderson Group Plc, and K2 Principal Fund L.P. have significantly reduced their holdings. Catalent has missed Q1 revenue estimate ahead of the deal with Novo Holdings. Post-acquisition, the Catalent CEO is expected to remain in charge. US Senator Warren is calling for scrutiny of the Catalent deal under Novo Holdings. The sale is generally perceived positively, and the likelihood of approval by EU for the deal has led to gains in the company's shares which reached a 52-week high of $61.55. Nevertheless, peers such as Eli Lilly (LLY) are considered to potentially bring higher returns.
Catalent CTLT News Analytics from Wed, 07 Feb 2024 08:00:00 GMT to Sat, 14 Dec 2024 19:18:12 GMT -
Rating 6
- Innovation -2
- Information 7
- Rumor -7
